Answers are grounded in this paper and cite their sources.
To analyze the cost-effectiveness of transcatheter aortic valve implantation (TAVI) using the SAPIEN 3 (Edwards Lifesciences, Irvine, CA) compared to surgical aortic valve replacement (SAVR) in low- and intermediate-risk patients from a Japanese public healthcare payer perspective.
No takes yet. Share an insight, caveat, or question.
Kobayashi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: